Search Results

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B, and age-related diseases, announced that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.

Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American depositary shares representing its ordinary shares.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.

Ascentage Pharma announced that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology Annual Meeting are now available on ASCO’s official website.

Ascentage Pharma announced that it has released updated results from a global, multicenter Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax alone or in combinations for the treatment of patients with Waldenström macroglobulinemia, in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Ascentage Pharma announced that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress.